Terremoto Biosciences

Ownership

Private

Employees

~35

Therapeutic Areas

Oncology

Stage

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Modalities

Small molecule medicines leveraging covalent chemistry, specifically lysine-based covalency

Terremoto Biosciences General Information

The company aims to deliver highly targeted small molecule medicines with optimized clinical profiles using a novel lysine-based covalent approach that broadens the universe of druggable targets. They emphasize rapid delivery of these medicines to patients through their platform[1][2][5]. No detailed clinical results are available as they appear still in discovery/preclinical phases.

Contact Information

Website

https://terremotobio.com/

Primary Industry

Biotech

Corporate Office

San Francisco, California
United States

Drug Pipeline

No pipeline data available

For full access to Terremoto Biosciences's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Terremoto Biosciences Funding

Deal Type	Date	Amount	Status	Stage
Investment	Apr 15, 2026	$108.0M	Completed	Preclinical

Early Stage VC (Series A)	04-Jun-2020	$38M	Completed	Phase 1
Seed Round	12-Feb-2019	$8.5M	Completed	Startup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more

To view Terremoto Biosciences's complete valuation and funding history, request access »